DK1504764T3 - Behandling af leverfibrose med antistoffer mod alfa-V-beta-6-integrin - Google Patents

Behandling af leverfibrose med antistoffer mod alfa-V-beta-6-integrin

Info

Publication number
DK1504764T3
DK1504764T3 DK04022921T DK04022921T DK1504764T3 DK 1504764 T3 DK1504764 T3 DK 1504764T3 DK 04022921 T DK04022921 T DK 04022921T DK 04022921 T DK04022921 T DK 04022921T DK 1504764 T3 DK1504764 T3 DK 1504764T3
Authority
DK
Denmark
Prior art keywords
integrin
antibodies
beta
alpha
treatment
Prior art date
Application number
DK04022921T
Other languages
English (en)
Inventor
Xiaozhu Huang
Dean Sheppard
Robert Pytela
Original Assignee
Univ California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ California filed Critical Univ California
Application granted granted Critical
Publication of DK1504764T3 publication Critical patent/DK1504764T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/39Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/10Drugs for disorders of the urinary system of the bladder
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70546Integrin superfamily
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01KANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00Genetically modified animals
    • A01K2217/05Animals comprising random inserted nucleic acids (transgenic)
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01KANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00Genetically modified animals
    • A01K2217/07Animals genetically altered by homologous recombination
    • A01K2217/075Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DK04022921T 1997-08-08 1998-08-07 Behandling af leverfibrose med antistoffer mod alfa-V-beta-6-integrin DK1504764T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US5506097P 1997-08-08 1997-08-08
PCT/US1998/016439 WO1999007405A1 (en) 1997-08-08 1998-08-07 TREATMENT OF ACUTE LUNG INJURY AND FIBROSIS WITH ANTAGONISTS OF αvβ6

Publications (1)

Publication Number Publication Date
DK1504764T3 true DK1504764T3 (da) 2008-11-17

Family

ID=21995323

Family Applications (2)

Application Number Title Priority Date Filing Date
DK04022921T DK1504764T3 (da) 1997-08-08 1998-08-07 Behandling af leverfibrose med antistoffer mod alfa-V-beta-6-integrin
DK08004714.5T DK1930022T3 (da) 1997-08-08 1998-08-07 Behandling af blærefibrose med antistoffer mod alfa-V-beta-6-integrin

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK08004714.5T DK1930022T3 (da) 1997-08-08 1998-08-07 Behandling af blærefibrose med antistoffer mod alfa-V-beta-6-integrin

Country Status (23)

Country Link
US (5) US20020004482A1 (da)
EP (3) EP1930022B1 (da)
JP (2) JP2001513333A (da)
KR (1) KR100586202B1 (da)
CN (1) CN1267224A (da)
AT (3) ATE410179T1 (da)
AU (1) AU739283B2 (da)
BR (1) BR9814040A (da)
CA (1) CA2297736A1 (da)
CY (2) CY1110462T1 (da)
CZ (1) CZ299768B6 (da)
DE (2) DE69828614T2 (da)
DK (2) DK1504764T3 (da)
EE (1) EE04752B1 (da)
ES (3) ES2235350T3 (da)
HU (1) HU228900B1 (da)
IL (2) IL134288A0 (da)
NZ (2) NZ515955A (da)
PL (2) PL199014B1 (da)
PT (3) PT1930022E (da)
RU (1) RU2221589C2 (da)
TR (2) TR200000374T2 (da)
WO (1) WO1999007405A1 (da)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5962643A (en) * 1991-07-11 1999-10-05 The Regents Of The University Of California Integrin β subunit and uses thereof
DE69828614T2 (de) * 1997-08-08 2006-02-09 The Regents Of The University Of California, Oakland Behandlung von Nierenfibrose durch Antikörper gegen integrin alpha-v-beta 6
CN1332714C (zh) * 1999-04-22 2007-08-22 比奥根艾迪克Ma公司 整联蛋白α4亚单位的拮抗剂在制备治疗纤维变性的药物组合物中的用途
DE19929410A1 (de) * 1999-06-26 2000-12-28 Merck Patent Gmbh Inhibitoren des Integrins avß6
US20030114410A1 (en) 2000-08-08 2003-06-19 Technion Research And Development Foundation Ltd. Pharmaceutical compositions and methods useful for modulating angiogenesis and inhibiting metastasis and tumor fibrosis
AUPR230500A0 (en) * 2000-12-22 2001-01-25 University Of Newcastle Research Associates Limited, The A method of modulating map kinase mediated cellular activity and agents useful in same
WO2002088307A2 (en) * 2001-04-30 2002-11-07 Eli Lilly And Company Humanized antibodies
WO2003100033A2 (en) * 2002-03-13 2003-12-04 Biogen Idec Ma Inc. ANTI-αvβ6 ANTIBODIES
WO2003087340A2 (en) * 2002-04-12 2003-10-23 Raven Biotechnologies, Inc. Antibodies that bind to integrin alpha-v-beta-6 and methods of use thereof
PT1734996E (pt) * 2004-04-02 2013-07-18 Univ California Métodos e composição para tratamento e prevenção de doenças associadas a integrina αvβ5
CN102875681A (zh) 2005-07-08 2013-01-16 拜奥根Idec马萨诸塞公司 抗-αvβ6抗体及其用途
US8795668B2 (en) * 2005-12-23 2014-08-05 The Regents Of The University Of Michigan Methods for treating pulmonary fibrosis
BRPI0714381A2 (pt) 2006-07-10 2013-03-05 Biogen Idec Inc composiÇÕes e mÉtodos para inibir crescimento de cÂnceres deficientes em smad4
ES2746925T3 (es) * 2006-08-03 2020-03-09 Medimmune Ltd Anticuerpos dirigidos hacia alfaVbeta6 y uso de los mismos
JP2010506944A (ja) * 2006-10-19 2010-03-04 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア インテグリンαVβ6のアンタゴニストを用いる慢性喘息の処置および予防
HUE025283T2 (en) 2007-08-02 2016-03-29 Gilead Biologics Inc LOX and LOX2 inhibitors and their use
KR101046317B1 (ko) * 2008-07-04 2011-07-05 이종대 조력발전 방법 및 그 장치
US9107935B2 (en) 2009-01-06 2015-08-18 Gilead Biologics, Inc. Chemotherapeutic methods and compositions
CN102481347A (zh) 2009-07-24 2012-05-30 加州大学董事会 治疗和预防整合素αvβ5相关疾病的方法及组合物
CA2771702A1 (en) 2009-08-21 2011-02-24 Gilead Biologics, Inc. Catalytic domains from lysyl oxidase and loxl2
NZ598464A (en) * 2009-08-21 2014-07-25 Gilead Biologics Inc Methods and compositions for treatment of pulmonary fibrotic disorders
KR20130008021A (ko) * 2010-02-04 2013-01-21 길리아드 바이오로직스, 인크. 리실 산화효소-유사 2 (loxl2)에 결합하는 항체, 및 그를 위한 사용 방법
AU2013221585B2 (en) 2012-02-17 2017-03-30 Seagen Inc. Antibodies to integrin alphavbeta6 and use of same to treat cancer
WO2014144466A1 (en) 2013-03-15 2014-09-18 Biogen Idec Ma Inc. Anti-alpha v beta 6 antibodies and uses thereof
US10035860B2 (en) 2013-03-15 2018-07-31 Biogen Ma Inc. Anti-alpha V beta 6 antibodies and uses thereof
EP2784511A1 (en) 2013-03-27 2014-10-01 Universität Zürich Integrin alpha-v-beta6 for diagnosis/prognosis of colorectal carcinoma
JP6104312B2 (ja) * 2014-06-19 2017-03-29 日東電工株式会社 組織再生促進剤
KR20200044066A (ko) 2017-08-22 2020-04-28 바이오젠 엠에이 인코포레이티드 항-알파(v)베타(6) 항체를 함유하는 약제학적 조성물 및 투약 요법
US11827709B2 (en) 2019-12-05 2023-11-28 Seagen Inc. Anti-AVB6 antibodies and antibody-drug conjugates

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US5019369A (en) 1984-10-22 1991-05-28 Vestar, Inc. Method of targeting tumors in humans
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5654270A (en) * 1988-06-28 1997-08-05 La Jolla Cancer Research Foundation Use of fibromodulin to prevent or reduce dermal scarring
JPH04503951A (ja) 1988-12-20 1992-07-16 ラ ホヤ キャンサー リサーチ ファウンデーション 創傷治癒に活性のあるポリペプチド―ポリマー複合体
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5514788A (en) * 1993-05-17 1996-05-07 Isis Pharmaceuticals, Inc. Oligonucleotide modulation of cell adhesion
US5962643A (en) 1991-07-11 1999-10-05 The Regents Of The University Of California Integrin β subunit and uses thereof
US5770565A (en) * 1994-04-13 1998-06-23 La Jolla Cancer Research Center Peptides for reducing or inhibiting bone resorption
US6492332B1 (en) * 1995-12-12 2002-12-10 Omeros Corporation Irrigation solution and methods for inhibition of tumor cell adhesion, pain and inflammation
PT719859E (pt) * 1994-12-20 2003-11-28 Merck Patent Gmbh Anticorpo monoclonal anti-alfa v-integrina
DE69828614T2 (de) * 1997-08-08 2006-02-09 The Regents Of The University Of California, Oakland Behandlung von Nierenfibrose durch Antikörper gegen integrin alpha-v-beta 6

Also Published As

Publication number Publication date
ATE410179T1 (de) 2008-10-15
US20020004482A1 (en) 2002-01-10
NZ515955A (en) 2003-04-29
CA2297736A1 (en) 1999-02-18
US20010056076A1 (en) 2001-12-27
DE69840113D1 (de) 2008-11-20
CZ2000413A3 (cs) 2000-11-15
HUP0003547A3 (en) 2002-05-28
PL199014B1 (pl) 2008-08-29
US20070148173A1 (en) 2007-06-28
KR20010022740A (ko) 2001-03-26
JP2009001587A (ja) 2009-01-08
HUP0003547A2 (hu) 2001-02-28
ATE511850T1 (de) 2011-06-15
IL134288A0 (en) 2001-04-30
ES2235350T3 (es) 2005-07-01
PT1930022E (pt) 2011-08-01
EP0996460A4 (en) 2001-03-07
PL201716B1 (pl) 2009-05-29
EP1930022B1 (en) 2011-06-08
EP0996460A1 (en) 2000-05-03
PT1504764E (pt) 2009-01-14
EP0996460B1 (en) 2005-01-12
WO1999007405A1 (en) 1999-02-18
DE69828614D1 (de) 2005-02-17
JP2001513333A (ja) 2001-09-04
DE69828614T2 (de) 2006-02-09
US20040208878A1 (en) 2004-10-21
EE200000068A (et) 2000-10-16
EP1504764B1 (en) 2008-10-08
EP1930022A1 (en) 2008-06-11
AU8774398A (en) 1999-03-01
ES2364703T3 (es) 2011-09-12
AU739283B2 (en) 2001-10-11
TR200000374T2 (tr) 2000-09-21
TR200202323T2 (tr) 2002-12-23
RU2221589C2 (ru) 2004-01-20
HU228900B1 (en) 2013-06-28
PT996460E (pt) 2005-04-29
CZ299768B6 (cs) 2008-11-19
ATE286742T1 (de) 2005-01-15
US6316601B1 (en) 2001-11-13
PL341029A1 (en) 2001-03-26
EE04752B1 (et) 2006-12-15
US7544358B2 (en) 2009-06-09
US7150871B2 (en) 2006-12-19
CY1111792T1 (el) 2015-10-07
CN1267224A (zh) 2000-09-20
NZ502546A (en) 2002-02-01
DK1930022T3 (da) 2011-07-25
BR9814040A (pt) 2000-10-03
IL134288A (en) 2008-07-08
KR100586202B1 (ko) 2006-06-07
CY1110462T1 (el) 2015-04-29
ES2311131T3 (es) 2009-02-01
EP1504764A1 (en) 2005-02-09
US6692741B2 (en) 2004-02-17

Similar Documents

Publication Publication Date Title
DK1504764T3 (da) Behandling af leverfibrose med antistoffer mod alfa-V-beta-6-integrin
DE60121988D1 (de) Kombinationstherapie mit antidiabetischen und antikonvulsiven mitteln
CY2010011I1 (el) Μορια αντισωματος που εμφανιζουν ειδικοτητα για ανθρωπινο παραγοντα νεκρωσης ογκων α, και χρηση αυτων
EE200300528A (et) Cripto valku blokeerivad antikehad ja nende kasutamine
DE69422102D1 (de) Wegwerfwindel in Höschenform
CY2009018I1 (el) Φαρμακευτικη συνθεση περιλαμβανουσα πιογλιταζονη και γλιμεπιριδη για χρηση στην θεραπεια του διαβητη
NO20002957L (no) Behandling med anti-ErbB2-antistoffer
FI961083A (fi) Rekombinentti-IL4-vasta-aineita, jotka ovat käyttökelpoisia IL-4-välitteisten häiriötilojen hoidossa
PL401886A1 (pl) Neutralizujace o wysokim powinowactwie izolowane ludzkie przeciwcialo anty-TNF-alfa, zastosowanie tego przeciwciala, krysztal zawierajacy ludzkie przeciwcialo anty-TNF-alfa i preparat zawierajacy ten krysztal
DE68912302D1 (de) Härtendes material für medizinischen und dentalen gebrauch.
SG136804A1 (en) Treatment of b cell malignancies using combination of b cell depleting antibody and immune modulating antibody related applications
PL371770A1 (en) Ganglioside-associated recombinant antibodies and the use thereof in the diagnosis and treatment of tumours
DE69940656D1 (de) Wegwerfwindel mit mechanischen Befestigungsmitteln
ATE336368T1 (de) Absorbierendes folienmaterial mit schnittfesten partikeln und verfahren zu dessen herstellung
EP1558284A4 (en) THERAPY ASSOCIATING CLASS III ANTI-ACE MONOCLONAL ANTIBODIES WITH THERAPEUTIC AGENTS
DE60022930D1 (de) Wegwerfwindel mit elastischen dichten Rändern
DE60006183D1 (de) Härtungsbeschleuniger und Harzzusammensetzung
TR200103432T2 (tr) Engelleyici monoklonal VLA-1 antikoru ve enflamasyonlu hastalıkların tedavisinde kullanımı.
DE60027413D1 (de) Herstellung von superabsorbierenden materialien in umgekehrten emulsionen mit grosser innerer phase
ITMI942663A0 (it) Proteine ricche in idrossiprolina e formulazioni farmaceutiche e cosmetiche che le compongono
DE69511148T2 (de) Wegwerfwindel mit verbessertem Abschluss an den Beinteilen
ID21895A (id) Antibodi yang mengikat kepada grup laminin yang mengikat nidogen, pembuatannya dan penggunaannya
EP1013642A3 (de) Chelatoren sowie deren Tricarbonyl-Komplexe mit Technetium und Rhenium
IS4387A (is) Nýtt skömmtunarform hýdroxókóbalamíns og notkun þess við sýaníðeitrunum
DK0900085T3 (da) Behandling af overdreven aggression med olanzapin